Sirnaomics Ltd (HKG: 2257), a leading company in the field of RNA therapeutics, has announced a strategic partnership with US-based Edirna Inc., a newly launched biotech startup focused on RNA editing therapy.
Funding and Licensing Agreement Details
Under the terms of the agreement, Sirnaomics is providing start-up funding to support Edirna’s initiatives. In return, Sirnaomics will have exclusive licensing rights to its proprietary delivery technologies for RNA-editing applications. This collaboration aims to leverage Sirnaomics’ expertise in delivery technologies to enhance the development of RNA editing therapies.
Edirna’s Proprietary Platform and Unmet Clinical Needs
Edirna Inc. offers the proprietary Edit to Cure Therapeutics delivery platform, which is designed to address diseases with unmet clinical needs. The partnership with Sirnaomics is expected to accelerate the advancement of these therapies and bring innovative solutions to the market.-Fineline Info & Tech
